Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Gbathaton Jul 05, 2021 7:36am
172 Views
Post# 33491887

selective pressure

selective pressureOne of the things that scares me regarding the current COVID situation is the concept of evolutionary selective pressure. Basically, when you have a large (vaccinated) population that is resistant to a disease mingling with a large population that is not resistant (unvaccinated), you have both a reservoir of the virus in which to propogate facing an increasing degree of selective pressure for mutants/variants that may evade the immunity mechanism. 

I thought this was a nice explanation of the issue.
https://www.mpg.de/16371358/coronavirus-variants

For this reason, I think it is critical to have tools like that being developed by PMN/BCNI via Immusafe and covidimmunitypassports.com 

I was really impressed that the immusafe prototype was updated so quickly to address the delta and other variants.  It seems to be an agile approach.
<< Previous
Bullboard Posts
Next >>